Anesthetic-induced unconsciousness is substantially accounted for by classical mechanisms — multi-target receptor and ion-channel pharmacology acting on network dynamics — with target-specific causal evidence for the intravenous agents.

Strongest causal evidence in the case at the level of target-specific manipulation, and assessed on that basis rather than on which side it favors. Two honest limits: the β3 result covers intravenous agents and transfers poorly to volatiles, and the claim's universal quantifier ("fully accounted for", "without any quantum contribution") is not established by successful conventional explanations, since a universally-quantified negative cannot be confirmed by accumulation.

Strong target-level causal evidence supports classical pharmacology, notably the finding that a single GABA_A β3 point mutation abolishes the immobilizing action of etomidate and propofol. The claim is heavily supported for intravenous agents, though the universal quantifier is limited by the fact that volatile agents act across broader targets. Its main vulnerability is explanatory rather than mechanistic: it offers no principled account of why classical network dynamics yield subjective experience.

The β3(N265M) GABA_A mutation abolishing etomidate/propofol-induced immobility and greatly attenuating hypnosis is strong, direct causal evidence for a classical receptor-based mechanism of intravenous anesthetics. Additional conventional work shows fractionation of endpoints across classical targets, cohering into a multi-target pharmacology that requires no quantum contribution. However, evidence for volatiles is less clean: the same mutation only modestly affects enflurane/halothane, and Li’s microtubule-modulator study shows that cytoskeletal perturbations can also modulate isoflurane sensitivity. Thus the claim that anesthetic unconsciousness and cognition are “fully accounted for” without any quantum-coherent contribution is well supported for intravenous agents, but remains more conjectural for volatiles and cannot be strictly proven as a universal negative. The main objection is that this account gives no principled explanation of why any such activity is conscious, nor of a characteristic conscious moment timescale.

Assessed as worded, including the universal quantifiers “fully” and “without any quantum-coherent contribution.” Target-level causal evidence for intravenous agents is strong: β3(N265M) abolishes etomidate and propofol immobility and greatly reduces hypnosis, and β2/β3 manipulations fractionate sedation, hypnosis, amnesia, and immobility. That standard is unmatched by any microtubule experiment in the file. The same mutation only slightly reduced enflurane and halothane, and Jurd et al. themselves conclude that volatiles act via a broader target spectrum — which is the agents most Orch OR experiments use. The xenon nuclear-spin isotope effect is a further anomaly for a pharmacology with no quantum degrees of freedom. The strongest opposing consideration is therefore the claim’s own wording: accumulating successful conventional mechanisms does not prove a universally quantified negative, and the hard-problem gap (why any of this activity is experienced) is acknowledged rather than closed.

The β3(N265M) point mutation abolishing etomidate and propofol immobility and profoundly reducing hypnosis is causal, target-specific evidence of a quality nothing else in the case approaches, and β2/β3 manipulations fractionate the anesthetic endpoints as the account predicts. The strongest opposing consideration comes from inside the same study: the mutation only slightly attenuated the volatile agents enflurane and halothane, whose broader target spectrum leaves genuine room for non-GABAergic contributions to the agents Orch OR experiments mostly use. The TREK-1 non-replication precedent is a further caution. These bound the claim's reach without dislodging its well-evidenced core; the exhaustive universal version is correctly quarantined in ORCH-C004.

I assess this below the label the case file itself carries, because the claim as worded contains a universal negative that the records do not reach. The core mechanistic content is genuinely strong: the β3(N265M) point mutation abolishes etomidate and propofol immobility and largely removes their hypnotic effect, which is target-level causal evidence no microtubule study here approaches. But the same mutation barely touches enflurane and halothane, so the result does not transfer to volatiles; the TREK-1 precedent shows genetic anesthetic-target findings can dissolve on replication; and ORCH-C025, if it survives, is a datum against "without any quantum-coherent contribution." A prior does unavoidable work here and I flag it: general decoherence physics makes a fully classical account the default expectation, and admitting that prior would raise this to well supported. On the records alone, the mechanism is well evidenced for intravenous agents and the universal quantifier is not established. The strongest opposing consideration is that the claim cannot be proved by accumulating successful conventional explanations at all — only defeated — so its evidential ceiling is structurally low.

ORCH-E015 remains the only target-level causal manipulation in the case, and the claim is worded narrowly enough ('substantially', intravenous agents) that the endpoint dissociation in ORCH-E030 refines rather than reduces it. Confidence held at moderate because transfer to volatile agents is not established.

ORCH-E015 remains the only target-level causal manipulation in the case, and the claim as worded is deliberately narrow — 'substantially', intravenous agents, multi-target pharmacology — so ORCH-E030's endpoint dissociation refines rather than reduces it. Held at moderate confidence because the transfer to volatile agents is not established.

ORCH-E015 remains the only target-level causal manipulation in the case, and the claim is worded narrowly enough ('substantially', intravenous agents) that the endpoint dissociation in ORCH-E030 refines rather than reduces it. Confidence held at moderate because transfer to volatile agents is not established.

Target-specific causal evidence exists for the classical account: a single engineered residue change in the GABA_A receptor β3 subunit abolishes the immobilizing action of etomidate and propofol and profoundly reduces their hypnotic effect. This represents a level of specific mechanistic intervention that the microtubule hypothesis completely lacks. The primary caveat is that this specific mutation only marginally affects volatile agents, which are the main focus of Orch OR experiments, leaving room for broader multi-target classical pathways.

The β3(N265M) knock-in work shows that removing sensitivity of β3 GABA_A receptors to etomidate and propofol abolishes immobility and greatly reduces hypnosis, which is strong causal evidence for a classical receptor-based mechanism for intravenous agents. The wider anesthetic literature supports a multi-target, ion-channel–centric view with endpoint fractionation that fits many data without invoking new physics. The main limiting factor is that these results do not fully generalize to volatile anesthetics or to all aspects of consciousness, and reviews like Eger et al. note that no single channel or combination yet suffices to explain volatile immobility; but that gap weakens only the exhaustive classical claim, not the “substantially accounted for” statement here.

Jurd et al. 2003 supply target-level causal evidence no microtubule experiment in this case approaches: a single β3(N265M) residue change abolishes etomidate- and propofol-induced immobility and profoundly reduces their hypnotic effect, with later mapping in the same line showing immobility abolished while loss-of-righting-reflex duration is reduced but not abolished. That is sufficient for the claim as worded, which asserts substantial classical accounting plus target-specific evidence for the intravenous agents, not an exhaustive negative over all possible contributions. The strongest opposing consideration is internal to the same literature: the mutation only slightly reduced enflurane and halothane effects, the authors themselves assign volatiles a broader target spectrum, and Eger et al. 2008 report that no known channel or combination suffices for inhaled-agent immobility.

The β3(N265M) point mutation abolishes etomidate- and propofol-induced immobility and profoundly reduces their hypnotic effect — a standard of target-level causal evidence no microtubule study in this case approaches — and β2/β3 manipulations dissociate sedation, hypnosis, amnesia, and immobility. Two honest qualifications are in the record: the same mutation only slightly reduced volatile agents' effects (the authors themselves conclude volatiles act via a broader target spectrum), and the TREK-1 episode shows genetic anesthetic-target findings can fail to replicate. The claim as worded says "substantially," which the evidence carries; the exhaustive version is correctly split to ORCH-C004. The strongest opposing consideration is that the receptor evidence is endpoint- and agent-specific — immobility is abolished while the hypnosis-adjacent endpoint is only reduced (ORCH-E030), and Eger 2008 concedes no known channel or combination suffices for volatile-induced immobility — so the conventional core is strong but not closed.

The β3(N265M) knock-in abolishes etomidate- and propofol-induced immobility and profoundly reduces their hypnotic effect, and β2/β3 manipulations dissociate sedation, hypnosis, amnesia and immobility — target-level causal evidence of a standard no microtubule study in this case approaches, and the claim as worded restricts the target-specific part to intravenous agents. Two qualifications keep confidence at moderate rather than high: ORCH-E030 shows the same line separates endpoints, with immobility abolished but the consciousness-adjacent endpoint reduced and not abolished; and the TREK-1 precedent shows genetic anesthetic-target findings can dissolve on replication. The strongest opposing consideration is ORCH-E031: the field's own flagship review reports that no channel, and no combination of channels, suffices to explain inhaled-agent immobility, which dents "substantially accounted for" outside the intravenous case.

ORCH-E015 remains the only target-level causal manipulation in the case; the claim's narrow wording ('substantially', intravenous agents) means the endpoint dissociation at ORCH-E030 refines rather than reduces it. Held at moderate confidence because transfer to volatile agents is not established.

ORCH-E015 remains the only target-level causal manipulation in the case; the claim's narrow wording ('substantially', intravenous agents) means the endpoint dissociation at ORCH-E030 refines rather than reduces it. Held at moderate confidence because transfer to volatile agents is not established.

Target-specific causal manipulation strongly supports the conventional mechanism, primarily through the β3(N265M) mutation which abolishes intravenous immobility (ORCH-E015, ORCH-E030). The strongest opposing consideration is the acknowledged gap within the conventional literature itself (ORCH-E031), which admits that no single channel or combination fully accounts for immobility from inhaled volatile agents.

The β3(N265M) mutation work (Jurd/Zeller: ORCH-E015/E030) provides textbook-quality causal evidence: a single amino-acid change in GABA_A β3 abolishes etomidate/propofol immobility and markedly reduces their hypnotic action, demonstrating that classical receptor/channel targets can substantially account for intravenous anesthetic-induced unconsciousness. Additional conventional literature, including Eger’s synthesis on inhaled-agent immobility (ORCH-E031), though incomplete, reinforces a multi-target channel/circuit picture. The strongest opposing consideration is that this evidence is endpoint- and drug-class-specific (intravenous, spinal immobility vs cortical “consciousness”) and leaves volatile agents less well explained, leaving room for other contributions without weakening the classical core.

The β3(N265M) point mutation abolishes the immobilizing action of etomidate and propofol and profoundly reduces their hypnotic effect, which is target-specific causal manipulation rather than correlational photophysics or latency shifts. β2/β3 genetic work further fractionates sedation, hypnosis, amnesia, and immobility, matching the claim's multi-target, network-dynamics framing for those agents. Two qualifications from inside the same literature keep this from "established": the mutation only slightly reduced enflurane and halothane, so the intravenous result does not transfer to the volatiles Orch OR experiments mostly use, and in the same knock-in line immobility is abolished while the consciousness-adjacent endpoint is reduced but not abolished. Strongest opposing consideration: Eger et al. report that no ligand- or voltage-gated channel, and no combination of them, suffices for inhaled immobility, and the authors of Jurd et al. themselves conclude that volatiles act via a broader target spectrum — an opening, not a microtubule demonstration.

The β3(N265M) point mutation abolishes etomidate- and propofol-induced immobility and profoundly reduces their hypnotic effect (ORCH-E015), with endpoint fractionation confirmed in the same knock-in line (ORCH-E030) — target-level causal evidence of a quality unmatched anywhere else in the case. Confidence is held at moderate because the claim as worded covers anesthetic-induced unconsciousness broadly while its best evidence is endpoint-specific: immobility is abolished, hypnosis reduced but not abolished, and the volatile agents were only slightly affected. The strongest opposing consideration is the conventional literature's own admission that no channel or combination suffices for volatile-induced immobility (ORCH-E031), plus the TREK-1 replication failure as a cautionary precedent for genetic target claims. The exhaustive version is correctly quarantined in ORCH-C004.

The β3(N265M) knock-in abolishes etomidate and propofol immobility and profoundly reduces their hypnotic effect (ORCH-E015) — target-level causal manipulation of a kind no microtubule result in this file approaches, and the claim is worded to restrict that strong evidence to the intravenous agents. Two honest limits are on the record: the same line separates endpoints, with the consciousness-adjacent measure reduced but not abolished (ORCH-E030), and the mutation barely touches volatile agents. The strongest opposing consideration is ORCH-E031, in which senior figures of the conventional literature report that no channel or combination suffices for inhaled immobility; that is why I grade confidence moderate rather than high, since "substantially accounted for" is markedly better evidenced for intravenous than for inhaled anesthesia.

ORCH-E015 remains the only target-level causal manipulation in the case, and the claim's narrow wording ('substantially', intravenous agents) means the endpoint dissociation at ORCH-E030 refines rather than reduces it. Held at moderate confidence because transfer to volatile agents is not established.

ORCH-E015 remains the only target-level causal manipulation in the case; the claim's narrow wording ('substantially', intravenous agents) means the endpoint dissociation at ORCH-E030 refines rather than reduces it. Held at moderate confidence because transfer to volatile agents is not established.

The conventional pharmacological account boasts target-level causal evidence, most notably the N265M GABA_A point mutation which abolishes propofol/etomidate immobility. The strongest opposing consideration is that this specific mutation only slightly reduces the hypnotic effects of volatile anesthetics, leaving an acknowledged gap where a multi-target or even microtubule-based volatile mechanism could operate.

The β3(N265M) knock-in experiments (ORCH-E015, ORCH-E030) show that a single point mutation in the GABA_A receptor β3 subunit abolishes etomidate and propofol immobility and markedly reduces their hypnotic effect, providing strong causal evidence that classical receptor mechanisms largely account for these agents’ anesthetic actions. This is reinforced by extensive pharmacology literature on multi-target channel and receptor contributions. The strongest opposing consideration is that for inhaled anesthetics and spinal immobility, Eger et al. (ORCH-E031) explicitly report that no single channel or combination suffices, so the conventional mechanistic account is incomplete for volatiles and cannot yet claim to exhaust all contributions.

Jurd et al. 2003 supply target-specific causal manipulation unmatched by any microtubule experiment in this file: the β3(N265M) point mutation abolishes etomidate- and propofol-induced immobility and profoundly reduces their hypnotic effect, and related β2/β3 work dissociates sedation, hypnosis, amnesia, and immobility. That is the standard of evidence the statement's intravenous clause requires. The strongest opposing consideration is internal to the same literature: the mutation only slightly reduced enflurane and halothane, the authors conclude that volatiles act via a broader target spectrum, hypnosis in the same knock-in is reduced but not abolished, and Eger et al. 2008 report that no channel combination suffices for inhaled immobility. Those limits belong on ORCH-C004; they do not erase the IV causal core as worded.

The β3(N265M) point mutation abolishes etomidate- and propofol-induced immobility and profoundly reduces their hypnotic effect (ORCH-E015) — target-level causal evidence of a quality no microtubule experiment in this case approaches — and β2/β3 manipulations dissociate the anesthetic endpoints from one another. The claim as worded is scoped to "substantially" with target-specific evidence "for the intravenous agents," and that is exactly where the evidence is strongest. The strongest opposing consideration comes from inside the same record: the mutation only slightly reduced enflurane and halothane effects, the authors themselves concluded volatile agents act through a broader target spectrum, and the conventional literature concedes no channel or combination suffices for inhaled-agent immobility (ORCH-E031) — so this claim's support does not transfer to the agents most Orch OR experiments use, which is why the exhaustive version is graded separately.

The β3(N265M) knock-in abolishes etomidate and propofol immobility and profoundly reduces their hypnotic effect (ORCH-E015) — target-level causal manipulation, which is the highest evidential grade present anywhere in this case, and the claim is deliberately scoped to the intravenous agents for exactly that reason. Endpoint dissociation within the same line (ORCH-E030) sharpens rather than undermines it, since the mutation's cleanest effect is on a spinal endpoint while hypnosis is reduced but not abolished. The strongest opposing consideration is ORCH-E031: the field's own flagship review reports that no channel, and no combination of channels, suffices to explain immobility from inhaled agents — so "substantially accounted for" is on firm ground for intravenous agents and considerably softer for the volatiles that most Orch OR experiments use.

ORCH-E015 remains the only target-level causal manipulation in the case, and the claim's narrow wording ('substantially', intravenous agents) means the endpoint dissociation in ORCH-E030 refines rather than reduces it. Confidence held at moderate because transfer to volatile agents is not established.

ORCH-E015 remains the only target-level causal manipulation in the case; the claim's narrow wording ('substantially', intravenous agents) means the endpoint dissociation at ORCH-E030 refines rather than reduces it. Held at moderate confidence because transfer to volatile agents is not established.

Evidence-only, and strongest exactly where Orch OR is weakest — at the level of target-specific causal manipulation. The β3(N265M) point mutation abolishes etomidate- and propofol-induced immobility and profoundly reduces their hypnotic effect (Jurd 2003), and β2/β3 manipulations dissociate sedation, hypnosis, amnesia, and immobility from one another. That is a standard of causal evidence no microtubule experiment in this case approaches. Two honest qualifications belong on the record, both from within the conventional literature: the same mutation only slightly reduced the effects of the volatile agents enflurane and halothane, so the intravenous result does not transfer to the agents Orch OR mostly concerns; and the TREK-1 story — initial knockout resistance later not reproduced — shows that apparently strong anesthetic-target claims can dissolve on genetic replication. The exhaustive version of this claim ("fully accounted for", "without any quantum-coherent contribution") lives separately as ORCH-C004, where those quantifiers are assessed on their own.

ORCH-E015 is the strongest causal record in the case: a single engineered residue change in the GABA_A β3 subunit abolishes the immobilizing action of etomidate and propofol and profoundly reduces their hypnotic effect. The claim is drafted narrowly — multi-target pharmacology on network dynamics, with target-specific causal evidence for the intravenous agents — and that is what the evidence delivers. ORCH-E030 sharpens rather than undercuts it: within the same knock-in line, immobility and the hypnosis surrogate come apart, so the cleanest part of the effect is a spinal endpoint. The claim's own scope excludes the volatile agents, for which the same paper's authors report a broader spectrum of targets.

Receptor-level point mutations, such as GABA_A β3(N265M), completely abolish the immobilizing and profoundly attenuate the hypnotic actions of intravenous anesthetics like etomidate and propofol in vivo. This provides direct target-level causal evidence that classical synaptic and network pharmacology mediates anesthesia. The strongest opposing consideration is that the same point mutation only minimally attenuates volatile anesthetics, which require a broader, partially unidentified set of targets as noted by Eger et al.

The β3(N265M) line is the cleanest causal evidence in the entire case — one residue change abolishes etomidate and propofol immobility and profoundly reduces hypnosis — and the Jurd/Zeller follow-up correctly separates the endpoints. The claim is scoped to "substantially" with the IV agents named, which matches the evidence. The boundary is real: the volatiles act through broader targets and Eger's immobility paradox shows no single channel suffices, so this is not a complete account.

ORCH-E015 provides target-specific causal evidence: a GABA_A β3 point mutation abolishes etomidate and propofol immobility and profoundly reduces their hypnotic action. The broader record supports multiple targets for volatile agents rather than one universal receptor mechanism. The strongest opposing consideration is ORCH-E030, which shows that the hypnosis endpoint is reduced rather than abolished, so classical receptor evidence does not exhaust every contribution.

Jurd et al. show a single GABA_A β3 point mutation abolishes immobilizing action and profoundly reduces hypnosis for etomidate and propofol, which is target-level causal evidence unmatched by any microtubule study in the ledger; the authors themselves limit clean transfer to volatiles. Strongest opposing consideration is that volatiles act via a broader target spectrum and that hypnosis is reduced rather than abolished, leaving a residual opening for additional mechanisms.

ORCH-E015 is target-level causal evidence: the β3(N265M) mutation abolishes etomidate and propofol immobility and sharply reduces hypnosis. ORCH-E030 qualifies it, since hypnosis is reduced rather than abolished. The claim is worded as 'substantially accounted for', with target-specific evidence for intravenous agents only, so both records fit it.